Related references
Note: Only part of the references are listed.Phase I Clinical and Magnetic Resonance Imaging Study of the Vascular Agent NGR-hTNF in Patients with Advanced Cancers (European Organization for Research and Treatment of Cancer Study 16041)
Hanneke W. M. van Laarhoven et al.
CLINICAL CANCER RESEARCH (2010)
Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours
Vanesa Gregorc et al.
EUROPEAN JOURNAL OF CANCER (2010)
Molecular therapy for the treatment of hepatocellular carcinoma
T. F. Greten et al.
BRITISH JOURNAL OF CANCER (2009)
Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours
V. Gregorc et al.
BRITISH JOURNAL OF CANCER (2009)
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
Ann-Lii Cheng et al.
LANCET ONCOLOGY (2009)
Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma
Abby B. Siegel et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Design and endpoints of clinical trials in hepatocellular carcinoma
Josep M. Llovet et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma
Melanie B. Thomas et al.
CANCER (2007)
Prognostic value of circulating chromogranin A and soluble tumor necrosis factor receptors in advanced nonsmall cell lung cancer
Vanesa Gregorc et al.
CANCER (2007)
Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma
Andrew X. Zhu et al.
CANCER (2007)
Impaired angiogenesis in aminopeptidase N-null mice
Roberto Rangel et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors
Yuval Shaked et al.
SCIENCE (2006)
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma
Ghassan K. Abou-Alfa et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: Five-year follow-up of Southwest Oncology Group protocol S9911
Oliver W. Press et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Synergistic antitumor activity of cisplatin, paclitaxel, and gemcitabine with tumor vasculature-targeted tumor necrosis factor-alpha
A Sacchi et al.
CLINICAL CANCER RESEARCH (2006)
Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer
PA Philip et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration
F Curnis et al.
JOURNAL OF CLINICAL INVESTIGATION (2002)
Enhancement of tumor necrosis factor a antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13)
F Curnis et al.
NATURE BIOTECHNOLOGY (2000)
Share Paper
